Purpose: The purpose of this study was to assess the effect on intraocular pressure (IOP) and the safety and tolerability of oromucosal administration of a low dose of delta-9-tetrahydrocannabinol (Delta-9-THC) and cannabidiol (CBD).
Results: Two hours after sublingual administration of 5 mg Delta-9-THC, the IOP was significantly lower than after placebo (23.5 mm Hg vs. 27.3 mm Hg, P=0.026). The IOP returned to baseline level after the 4-hour IOP measurement. CBD administration did not reduce the IOP at any time. However, the higher dose of CBD (40 mg) produced a transient elevation of IOP at 4 hours after administration, from 23.2 to 25.9 mm Hg (P=0.028). Vital signs and visual acuity were not significantly changed. One patient experienced a transient and mild paniclike reaction after Delta-9-THC administration.
Patients and methods: A randomized, double-masked, placebo-controlled, 4 way crossover study was conducted at a single center, using cannabis-based medicinal extract of Delta-9-THC and CBD. Six patients with ocular hypertension or early primary open angle glaucoma received a single sublingual dose at 8 AM of 5 mg Delta-9-THC, 20 mg CBD, 40 mg CBD, or placebo. Main outcome measure was IOP. Secondary outcomes included visual acuity, vital signs, and psychotropic effects.
Conclusions: A single 5 mg sublingual dose of Delta-9-THC reduced the IOP temporarily and was well tolerated by most patients. Sublingual administration of 20 mg CBD did not reduce IOP, whereas 40 mg CBD produced a transient increase IOP rise.
by Patrick J. Kiger, AARP, January 24, 2019
A recent study suggests that the marijuana product might worsen the condition
En español | Cannabidiol, or CBD, a chemical component of marijuana and hemp that doesn’t get users high, is increasingly touted by proponents as an alternative treatment for numerous ailments. But an organization of eye doctors is advising people not to try CBD as a remedy for glaucoma, a disease for which older Americans are at higher risk.
“Don’t use CBD as a ‘natural’ glaucoma remedy," the American Academy of Ophthalmology warned in a press statement pegged to Glaucoma Awareness Month.
Often touted as a magical elixir, CBD is being marketing as a treatment for just about everything, including anxiety, insomnia, pain, and even cancer. According to AARP, baby boomers are fueling the popularity of CBD and using it as a treatment for pain, arthritis and other age-related health problems.
CBD, short for a chemical in the cannabis plant called cannabidiol, has become all the rage over the past year. Available in oils, sprays, creams, and even bath bombs and dog treats, CBD does not make you high, unlike its well-known cannabinoid cousin, THC (tetrahydrocannabinol).
The study suggests that CBD doesn’t lower eye pressure, it raises it, which is problematic because high eye pressure is the primary risk factor for glaucoma. High eye pressure from glaucoma damages the optic nerve, which is responsible for allowing us to see by transmitting visual information to the brain. Increased eye pressure damages the nerve, leading to permanent vision loss.